Literature DB >> 9655116

Alternative dystrophin gene transcripts in golden retriever muscular dystrophy.

S J Schatzberg1, L V Anderson, S D Wilton, J N Kornegay, C J Mann, G G Solomon, N J Sharp.   

Abstract

Golden retriever muscular dystrophy (GRMD), the canine model of Duchenne muscular dystrophy (DMD), is caused by a splice site mutation in the dystrophin gene. This mutation predicts a premature termination codon in exon 8 and a peptide that is 5% the size of normal dystrophin. Western blot analysis of skeletal muscle from GRMD dogs reveals a slightly truncated 390-kD protein that is approximately 91% the size of normal dystrophin. This 390-kD dystrophin suggests that GRMD dogs, like some DMD patients, employ a mechanism to overcome their predicted frameshift. Reverse-transcriptase polymerase chain reaction on GRMD muscle has revealed two in-frame dystrophin transcripts which lack either exons 3-9 or exons 5-12. Both transcripts could be translated into a dystrophin protein of approximately 390 kD. An understanding of how truncated dystrophin is produced in GRMD may allow this mechanism to be manipulated toward a potential therapy for DMD.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9655116     DOI: 10.1002/(sici)1097-4598(199808)21:8<991::aid-mus2>3.0.co;2-0

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  19 in total

Review 1.  Porcine models of muscular dystrophy.

Authors:  Joshua T Selsby; Jason W Ross; Dan Nonneman; Katrin Hollinger
Journal:  ILAR J       Date:  2015

Review 2.  Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials.

Authors:  Joe N Kornegay; Christopher F Spurney; Peter P Nghiem; Candice L Brinkmeyer-Langford; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  ILAR J       Date:  2014

3.  Hydrodynamic limb vein injection of adeno-associated virus serotype 8 vector carrying canine myostatin propeptide gene into normal dogs enhances muscle growth.

Authors:  Chunping Qiao; Juan Li; Hui Zheng; Janet Bogan; Jianbin Li; Zhenhua Yuan; Cheng Zhang; Dan Bogan; Joe Kornegay; Xiao Xiao
Journal:  Hum Gene Ther       Date:  2009-01       Impact factor: 5.695

4.  Kinematics of gait in golden retriever muscular dystrophy.

Authors:  Anthony P Marsh; Joel D Eggebeen; Joe N Kornegay; Chad D Markert; Martin K Childers
Journal:  Neuromuscul Disord       Date:  2009-11-22       Impact factor: 4.296

5.  Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping.

Authors:  Adeline Vulin; Inès Barthélémy; Aurélie Goyenvalle; Jean-Laurent Thibaud; Cyriaque Beley; Graziella Griffith; Rachid Benchaouir; Maëva le Hir; Yves Unterfinger; Stéphanie Lorain; Patrick Dreyfus; Thomas Voit; Pierre Carlier; Stéphane Blot; Luis Garcia
Journal:  Mol Ther       Date:  2012-09-11       Impact factor: 11.454

Review 6.  Gene and cell-mediated therapies for muscular dystrophy.

Authors:  Patryk Konieczny; Kristy Swiderski; Jeffrey S Chamberlain
Journal:  Muscle Nerve       Date:  2013-03-29       Impact factor: 3.217

7.  Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse.

Authors:  C J Mann; K Honeyman; A J Cheng; T Ly; F Lloyd; S Fletcher; J E Morgan; T A Partridge; S D Wilton
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

8.  Revertant fibers in the mdx murine model of Duchenne muscular dystrophy: an age- and muscle-related reappraisal.

Authors:  Sarah R Pigozzo; Lorena Da Re; Chiara Romualdi; Pietro G Mazzara; Eva Galletta; Sue Fletcher; Stephen D Wilton; Libero Vitiello
Journal:  PLoS One       Date:  2013-08-28       Impact factor: 3.240

9.  A duchenne muscular dystrophy gene hot spot mutation in dystrophin-deficient cavalier king charles spaniels is amenable to exon 51 skipping.

Authors:  Gemma L Walmsley; Virginia Arechavala-Gomeza; Marta Fernandez-Fuente; Margaret M Burke; Nicole Nagel; Angela Holder; Rachael Stanley; Kate Chandler; Stanley L Marks; Francesco Muntoni; G Diane Shelton; Richard J Piercy
Journal:  PLoS One       Date:  2010-01-13       Impact factor: 3.240

10.  Novel compounds for the treatment of Duchenne muscular dystrophy: emerging therapeutic agents.

Authors:  Steve D Wilton; Sue Fletcher
Journal:  Appl Clin Genet       Date:  2011-03-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.